FDA blog aims to chronicle transparency push

FDA said it wanted to be more "transparent," more "open" about its decision-making. Already, the agency has launched a blog to detail its quest for transparency--and solicit input from the public. Enter your comments at will, but remember: no vulgar language allowed. Release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.